TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

18.52 Smith DE et al. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS 2004;18:709-18. 18.53 Centers for Disease Control and Prevention (CDC). Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged
18.91 Lesho E. Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. Expert Rev Anti Infect Ther 2006;4:469-78. 18.92 Robertson J et al. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006;42:1639-46. 18.93 Puthanakit T et al. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus infected Thai children. Pediatr Infect Dis J 2006;25:53-8. 18.94 Lipman M et al. Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis 2006;19: 20-5. 18.95 Burgoyne RW et al. Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act. J Antimicrob Chemother 2008;61:469-73. 18.96 The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96. 18.97 Eron JJ. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. J Infect Dis 2008;197(suppl. 3):S261-71. 18.98 Temesgen Z et al. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. Lancet Infect Dis 2006;6:496-507. 18.99 Gallant JE. Approach to the treatment-experienced patient. Infect Dis Clin North Am 2007;21:85- 102. 18.100 Paton NI. Treatment interruption strategies: how great are the risks? Curr Opin Infect Dis 2008;21: 25-30. 18.101 Wilson LE et al. The Management of treatment-experienced HIV-infected patients: new drugs and drug combinations. Clin Infect Dis 2009;48:214-21. 18.102 Eron JJ. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. J Infect Dis 2008;197(suppl. 3):S261-71. 18.103 Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at: http://aids info.nih.gov/contentfiles/PerinatalGL.pdf. Accessed on August 18 th 2010. 18.104 Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Tables. Available at: http: //aidsinfo.nih.gov/contentfiles/Peri_Tables.pdf. Accessed on August 18 th 2010. 18.105 Centers for Disease Control and Prevention (CDC). Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged
Page 1 and 2:
TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4:
1.89 Laupland KB. Vascular and para
Page 5 and 6:
of NICE guidance. Br Med J 2008;337
Page 7 and 8:
tions à Clostridium difficile dans
Page 9 and 10:
sis of placebo-controlled trials. C
Page 11 and 12:
1.446 Centers for Disease Control a
Page 13 and 14:
1.532 Olaison L et al. Enterococcal
Page 15 and 16:
1.615 Muder RR et al. Isolation of
Page 17 and 18:
2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20:
2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22:
1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25 and 26: of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73: 18.12 Panel on Antiretroviral Thera
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80: duct characteristics. Available at:
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88: 1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90: 21.358 Calabrese LH et al. Viral Ar
Page 91 and 92: 24. 21.452 Jeha LE et al. Long term
Page 93 and 94: induced functional androgen deficie
Page 95 and 96: 25A.27 Conseil Supérieur de la San
Page 97 and 98: product characteristics. Available
Page 99 and 100: mortality after kidney transplantat
Page 101 and 102: 33A.1 Kearney BP et al. The penetra
Page 103 and 104: Clin Plast Surg Clinics in Plastic
Page 105 and 106: Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?